Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$1.04 -2.8%	$0.96	$0.69 ▼ $3.94	$212.07M	0.67	5.17 million shs	3.06 million shs
KNTE Kinnate Biopharma	$2.65	$2.61	$1.04 ▼ $7.18	$125.13M	1.38	418,678 shs	N/A
LMDX LumiraDx		$0.01	$0.02 ▼ $1.33	$5.10M	1.73	56.75 million shs	132.24 million shs
VSTM Verastem	$4.62 -6.3%	$6.70	$2.10 ▼ $9.10	$270.90M	0.85	1.19 million shs	2.91 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	-2.80%	-11.11%	+31.60%	-38.10%	-52.94%
KNTE Kinnate Biopharma	0.00%	0.00%	0.00%	0.00%	0.00%
LMDX LumiraDx	0.00%	0.00%	0.00%	0.00%	0.00%
VSTM Verastem	-6.29%	-18.09%	-44.40%	-29.68%	+46.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	4.0991 of 5 stars	3.4	3.0	0.0	3.9	2.4	1.7	0.6
KNTE Kinnate Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LMDX LumiraDx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	2.1356 of 5 stars	3.5	2.0	0.0	0.0	0.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	573.08% Upside
KNTE Kinnate Biopharma	0.00	N/A	N/A	N/A
LMDX LumiraDx	0.00	N/A	N/A	N/A
VSTM Verastem	3.00	Buy	$13.63	194.91% Upside

Current Analyst Ratings Breakdown

Latest ESPR, KNTE, LMDX, and VSTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/24/2025	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $14.00
3/24/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	0.62	$0.02 per share	44.53	($1.97) per share	-0.53
KNTE Kinnate Biopharma	N/A	N/A	N/A	N/A	$5.06 per share	N/A
LMDX LumiraDx	$126.52M	0.00	N/A	N/A	($0.33) per share	0.00
VSTM Verastem	$10K	25,386.90	N/A	N/A	($0.65) per share	-7.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
KNTE Kinnate Biopharma	-$116.27M	-$2.78	N/A	N/A	N/A	N/A	-62.31%	-54.72%	N/A
LMDX LumiraDx	-$447.79M	-$1.09	N/A	N/A	N/A	-268.45%	N/A	-77.91%	N/A
VSTM Verastem	-$130.64M	-$3.20	N/A	N/A	N/A	N/A	-2,003.62%	-127.97%	8/6/2025 (Estimated)

Latest ESPR, KNTE, LMDX, and VSTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
KNTE Kinnate Biopharma	N/A	N/A	N/A	N/A	N/A
LMDX LumiraDx	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.18	0.81
KNTE Kinnate Biopharma	N/A	10.80	10.80
LMDX LumiraDx	N/A	0.45	0.23
VSTM Verastem	2.77	3.50	3.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
KNTE Kinnate Biopharma	80.89%
LMDX LumiraDx	9.59%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
KNTE Kinnate Biopharma	41.70%
LMDX LumiraDx	35.41%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
KNTE Kinnate Biopharma	84	47.22 million	27.53 million	Optionable
LMDX LumiraDx	1,210	318.55 million	205.75 million	Not Optionable
VSTM Verastem	50	54.95 million	53.80 million	Optionable

ESPR, KNTE, LMDX, and VSTM Headlines

Recent News About These Companies

Financial Contrast: Verastem (NASDAQ:VSTM) vs. Ensysce Biosciences (NASDAQ:ENSC)

June 16, 2025 | americanbankingnews.com

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges

June 15, 2025 | investing.com

Verastem reports promising cancer drug trial results

June 4, 2025 | investing.com

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

June 4, 2025 | businesswire.com

Verastem’s Promising Clinical Advances and Strategic Developments Justify Buy Rating

June 3, 2025 | tipranks.com

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Buy" from Brokerages

June 3, 2025 | marketbeat.com

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

June 2, 2025 | msn.com

Verastem Announces Strategic Plans in Investor Webcast

June 2, 2025 | tipranks.com

What's Going On With Verastem Oncology Stock On Monday?

June 2, 2025 | benzinga.com

Verastem, Inc. (NASDAQ:VSTM) Short Interest Update

June 2, 2025 | marketbeat.com

Verastem Announces Promising Phase 1 Study Results

June 2, 2025 | tipranks.com

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

June 2, 2025 | businesswire.com

Investors Buy Large Volume of Verastem Call Options (NASDAQ:VSTM)

May 31, 2025 | marketbeat.com

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

May 28, 2025 | zacks.com

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 28, 2025 | businesswire.com

Northern Trust Corp Boosts Holdings in Verastem, Inc. (NASDAQ:VSTM)

May 28, 2025 | marketbeat.com

723,806 Shares in Verastem, Inc. (NASDAQ:VSTM) Bought by Woodline Partners LP

May 27, 2025 | marketbeat.com

BNP Paribas Financial Markets Makes New $387,000 Investment in Verastem, Inc. (NASDAQ:VSTM)

May 27, 2025 | marketbeat.com

Verastem’s SWOT analysis: biotech firm’s stock poised for growth amid challenges

May 23, 2025 | investing.com

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline ...

May 23, 2025 | finance.yahoo.com

Verastem expands ambitions with strong pancreatic cancer data at ASCO

May 23, 2025 | thepharmaletter.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR, KNTE, LMDX, and VSTM Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$1.04 -0.03 (-2.80%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$1.04 0.00 (0.00%)

As of 06/23/2025 07:59 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Kinnate Biopharma NASDAQ:KNTE

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

LumiraDx NASDAQ:LMDX

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.

Verastem NASDAQ:VSTM

$4.62 -0.31 (-6.29%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$4.65 +0.03 (+0.74%)

As of 06/23/2025 07:56 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time